Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of erlotinib + bevacizumab as first-line treatment for advanced non-small cell lung cancer
ISRCTN78329606Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Primary endpoint: Rate of no progression at 6 weeks. Started Jan 2006; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN78329606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78329606.